Liposomal Irinotecan and Apatinib in ES-SCLC

The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

Trial Details

NCT ID
NCT06749691
Phase
PHASE2
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Liposomal Irinotecan and Apatinib
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age range of 18-75 years;
  • Expected survival period ≥ 12 weeks;
  • At least one measurable lesion (according to RECIST V 1.1);
  • For patients who have failed first-line or second-line treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →